title: Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center.
authors.affiliation: DiBiMis, Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo University, Palermo, Italy.
authors.forename: Ambrogio
authors.initials: A
authors.lastname: Orlando
authors.affiliation: DiBiMis, Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo University, Palermo, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Renna
authors.affiliation: DiBiMis, Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo University, Palermo, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Rizzuto
authors.affiliation: DiBiMis, Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo University, Palermo, Italy.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Orlando
authors.affiliation: DiBiMis, Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo University, Palermo, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Affronti
authors.affiliation: DiBiMis, Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo University, Palermo, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Cottone
mesh_terms: D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000379:methods*; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000008:administration & dosage*; D062606:Tertiary Care Centers; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab